Esperion Therapeutics to be Acquired by ARCHIMED for $3.16/Share Cash Plus CVRs
Summary
Esperion Therapeutics has entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus contingent value rights (CVRs) up to $100 million.
Key Events
-
Definitive Merger Agreement Announced
Esperion Therapeutics, Inc. has entered into a definitive agreement to be acquired by ARCHIMED (Essence Parent Inc.).
-
Acquisition Terms Detailed
Shareholders will receive $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100 million in aggregate, tied to future net sales performance.
-
Anticipated Closing in Q3 2026
The transaction is anticipated to close in the third quarter of 2026, subject to customary closing conditions and stockholder approval.
-
CEO Communicates Internally
The filing includes an email from CEO Sheldon Koenig to all company employees, announcing the acquisition and outlining next steps, including a virtual Town Hall meeting.
Analysis
This DEFA14A filing officially confirms and details the definitive agreement for Esperion Therapeutics to be acquired by ARCHIMED (Essence Parent Inc.). The acquisition, previously reported in news outlets today, offers shareholders $3.16 per share in cash, representing a slight premium to the current stock price, along with contingent milestone payments up to $100 million. This transaction fundamentally alters the company's future, providing immediate cash value and potential upside through CVRs, and is expected to close in the third quarter of 2026. The filing includes an internal CEO email to employees, signaling the formal communication of this major corporate event.
At the time of this filing, ESPR was trading at $3.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $801.8M. The 52-week trading range was $0.69 to $4.18. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.